Sugi Predict

Sugi Predict / Compounds / SCHEMBL1440133

SCHEMBL1440133

SCHEMBL1440133

CC(C)(C)OC(=O)N1C[C@H](O[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)C[C@@H]1CO

nearest known ligand 0.47

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 12/20 0.47
▸ ABCB1 P08183 1/20 0.42
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ UCHL1 P09936 1/20 0.38
▸ PARP1 P09874 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ JAK1 P23458 1/20 0.37
▸ TACR1 P25103 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1464254 1.00 SRC (0.47) SRCABCB1MEN1KMT2AUCHL1
SCHEMBL30646013 1.00 SRC (0.47) SRCABCB1MEN1KMT2AUCHL1
SCHEMBL1439291 1.00 SRC (0.47) SRCABCB1MEN1KMT2AUCHL1
SCHEMBL30645851 1.00 SRC (0.47) SRCABCB1MEN1KMT2AUCHL1
SCHEMBL30645862 0.92 ABCB1 (0.41) SRCABCB1MEN1KMT2AUCHL1
SCHEMBL30803114 0.90 ABCB1 (0.41) SRCABCB1MEN1KMT2AUCHL1
SCHEMBL1465568 0.89 UCHL1 (0.41) SRCABCB1MEN1KMT2AUCHL1
SCHEMBL1439614 0.89 UCHL1 (0.41) SRCABCB1MEN1KMT2AUCHL1
SCHEMBL13721651 0.89 SRC (0.35) SRCABCB1
SCHEMBL29535652 0.89 SRC (0.35) SRCABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116891-A1 Oxazepin Derivative TEIJIN PHARMA LTD (JP) 2026-04-30 — — US disclosed
US-20250333399-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KHORA SPV 1 LLC (US) 2025-10-30 — — US disclosed
US-12331039-B2 Inhibitors of fibroblast growth factor receptor kinases KHORA SPV 1, LLC (US) 2025-06-17 — — US disclosed
EP-4512811-A1 OXAZEPINE DERIVATIVE Teijin Pharma Limited (JP) 2025-02-26 — — EP disclosed
US-20230374015-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KINNATE BIOPHARMA INC. 2023-11-23 — — US disclosed
WO-2023204308-A1 OXAZEPINE DERIVATIVE 帝人ファーマ株式会社 2023-10-26 — — WO disclosed
US-20230174535-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KINNATE BIOPHARMA INC. 2023-06-08 — — US disclosed
US-20230174535-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KINNATE BIOPHARMA INC. 2023-06-08 — — US disclosed
CN-116096707-A Inhibitors of fibroblast growth factor receptor kinase 金耐特生物制药公司 2023-05-09 — — CN disclosed
CN-116057045-A Fibroblast growth factor receptor kinase inhibitors 金耐特生物制药公司 2023-05-02 — — CN disclosed
WO-2012101063-A1 N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2012-08-02 — — WO disclosed
EP-2473505-A1 PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-07-11 — — EP disclosed
EP-2473502-A1 HETEROARYL COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2012-07-11 — — EP disclosed
EP-2473499-A1 BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-07-11 — — EP disclosed
US-20120165306-A1 PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-06-28 — — US disclosed
US-20120157433-A1 Heteroaryl Compounds as Kinase Inhibitors PFISTER KEITH B (US) 2012-06-21 — — US disclosed
US-20110130380-A1 Heteroaryl Kinase Inhibitors NOVARTIS AG (CH) 2011-06-02 — — US disclosed
WO-2011026911-A1 BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2011-03-10 — — WO disclosed
WO-2011026904-A1 PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2011-03-10 — — WO disclosed
WO-2011026917-A1 HETEROARYL COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2011-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174535-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES FGFR1, FGFR2, FGFR3 SRC 28/4885ABCB1 1125/4885MEN1 2465/4885
US-20230374015-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES FGFR1, FGFR2, FGFR3 SRC 30/4885ABCB1 796/4885MEN1 2735/4885
US-12331039-B2 Inhibitors of fibroblast growth factor receptor kinases FGFR1, FGFR2, FGFR3 SRC 30/4885ABCB1 796/4885MEN1 2735/4885
US-20250333399-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES FGFR1, FGFR2, FGFR3 SRC 30/4885ABCB1 796/4885MEN1 2735/4885
US-20120157433-A1 Heteroaryl Compounds as Kinase Inhibitors CDK2, CDK1, CDK6 SRC 334/4885ABCB1 666/4885MEN1 1807/4885
US-20110130380-A1 Heteroaryl Kinase Inhibitors CDK2, CDK1, CDKL1 SRC 517/4885ABCB1 576/4885MEN1 2654/4885
US-20120165306-A1 PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES CDK4, CDK1, CCNI SRC 2207/4885ABCB1 1539/4885MEN1 1282/4885
US-20260116891-A1 Oxazepin Derivative HCRTR2, HCRTR1, OXTR SRC 2905/4885ABCB1 2006/4885MEN1 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.